COMPANY SUMMARY BIO Boston 1x1 meeting GENEURO ___________ NAME - PDF document

COMPANY SUMMARY BIO Boston 1x1 meeting GENEURO ___________ NAME OF THE CEO Jesús MARTIN-GARCIA MISSION GeNeuro is a clinical-stage biopharmaceutical company focused on stopping autoimmune and neurodegenerative diseases such as multiple sclerosis (MS) and type 1 diabetes (T1D) by neutralizing causal factors encoded by human endogenous retroviruses (HERV), which represent 8% of the human DNA. TECHNOLOGY Its most advanced therapeutic candidate, GNbAC1, is an antibody that neutralizes a pathogenic protein of the HERV-W family (pHERV-W Env) that has been identified as a potential causal factor in MS and T1D. GeNeuro communicated successful results of a Phase IIb in MS in March, and expects results of a Phase IIa in T1D in 3Q18. ADRESS COMPETITION 3 Chemin du Pré-Fleuri CH-1228 Plan-les-Ouates GeNeuro is the front runner in the HERV field, protected by 16 families of Geneva, Switzerland patents. _____________________ ALLIANCES/PARTNERSHIPS EMAIL contact@geneuro.com € 362 million partnership with Servier in 2014. This agreement relates solely to MS www.geneuro.com and does not cover the US market nor the applications of GeNeuro’s technology in other indications, for which all rights have been retained by GeNeuro MANAGEMENT TEAM UPCOMING CATALYSTS CEO: Jesús Martin-Garcia CFO: Miguel Payró - New anti-pHERV antibodies (e.g. ALS, inflammatory psychosis) CMO: Robert Glanzman - T1D Phase IIa results 3Q2018 - US IND & opening Phase II trial in Secondary Progressive MS patients - Resolution of Servier’s option to license GNbAC1 in MS ex-US and ex-Japan TARGETED MARKET MARKET FIGURES ____________ Revenues 2017: € 14.9 million MS, T1D, Chronic Inflammatory Date of IPO: April 16, 2016 Ticker: GNRO Demyelinating Polyneuropathy Exchange: EURONEXT PARIS (CIDP), ALS Currency: EUR Market cap: € 90 million Price: € 6.16 LISTED COMPANY 52-weeks-high: € 12.92 52-weeks-low: € 3.91 Average daily volume: 3’981 CREATION DATE KEY FIGURES April 2006 € m 2016 2017 Sales 5.9 14.9 EBIT (14.0) (5.7) Net Income (14.1) (5.8) Cash Position 34.5 26.6

COMPANY SUMMARY BIO Boston 1x1 meeting GENEURO ___________ NAME OF THE CEO Jesús MARTIN-GARCIA ANALYST COVERAGE Broker Date Reco. Target Price Potential (%) (buy/neutral/hold ) Bryan Garnier March 26 BUY 16.5 +168% Gilbert Dupont March 26 REDUCE 8 +30% Kepler April 4 BUY 9.9 +61% Cheuvreux Average: - - 11.5 +87% SHAREHOLDERS (percentage) ADRESS 3 Chemin du Pré-Fleuri CH-1228 Plan-les-Ouates Geneva, Switzerland _____________________ EMAIL contact@geneuro.com www.geneuro.com MANAGEMENT TEAM CEO: Jesús Martin-Garcia CFO: Miguel Payró CMO:Robert Glanzman PIPELINE TARGETED MARKET ____________ MS, T1D, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), ALS LISTED COMPANY CREATION DATE April 2006

COMPANY SUMMARY BIO Boston 1x1 meeting GENEURO ___________ NAME OF THE CEO Jesús MARTIN-GARCIA ANALYST COVERAGE Broker Date Reco. Target Price Potential (%) (buy/neutral/hold ) Bryan Garnier March 26 BUY 16.5 +168% Gilbert Dupont March 26 REDUCE 8 +30% Kepler April 4 BUY 9.9 +61% Cheuvreux Average: - - 11.5 +87% SHAREHOLDERS (percentage) December 31, 2017 Shareholders % of capital and voting rights Eclosion2 & Cie SCPC 43.44% ADRESS Institut Mérieux 27.48% 3 Chemin du Pré-Fleuri Servier International BV 8.56% bioMérieux SA 6.40% CH-1228 Plan-les-Ouates Treasury shares 0.47% Geneva, Switzerland Publicly held 12.15% _____________________ Employees & directors 1.50% EMAIL TOTAL 100.00% contact@geneuro.com PIPELINE www.geneuro.com MANAGEMENT TEAM CEO: Jesús Martin-Garcia CFO: Miguel Payró CMO:Robert Glanzman TARGETED MARKET ____________ MS, T1D, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), ALS LISTED COMPANY CREATION DATE April 2006